This bill proposes to permanently classify the entire class of benzimidazole-opioids , known as nitazenes, as Schedule I controlled substances under the Controlled Substances Act. These synthetic opioids are recognized for their significant potency, with some exceeding that of fentanyl, and have emerged in the illicit drug supply contributing to overdose fatalities. The legislation aims to address their high abuse potential and lack of accepted medical use by ensuring their permanent placement in the most restrictive schedule. The bill provides a detailed structural definition for 2-benzylbenzimidazole opioids, including specific modifications and examples like etonitazene and isotonitazene, to ensure a comprehensive class-wide scheduling. This approach is intended to preemptively address the proliferation of new analogs , streamline enforcement efforts, and safeguard public health. Furthermore, any nitazene compounds previously temporarily scheduled by the DEA will automatically convert to permanent Schedule I status upon the bill's enactment, while clarifying that new research still requires proper registration.